Virbac has announced that the European Medicines Agency has granted a 3 year duration of immunity for the feline leukaemia component of both Leucogen and Leucofeligen vaccines, when given after the primary course and first annual booster.

Leucogen is the world’s first recombinant subunit vaccine containing purified p45 FeLV-envelope antigen. Leucofeligen is a fully authorised combination vaccine for FeLV, rhinotracheitis, calicivirus and the feline panleucopaenia virus. 

Virbac says that once into the 3 year immunity period for FeLV, cats may be given annual boosters against feline rhinotracheitis calicivirus and panleucopenia in the intervening years with Feligen RCP.

Tara Smith, Product Manager at Virbac UK, said: "This is a great development for Leucogen and Leucofeligen. We’re really excited to show practices the practical benefits that this extended duration of immunity offers, from improving the profitability of pet health plans to adapting the vaccine programme to suit the cat’s needs".

For more information, contact your Virbac Territory Manager.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.